About us
Fastox is a Swiss biotechnology start-up created by seasoned experts in biotech and botulinum neurotoxins.
​
Millions of treatments with botulinum neurotoxin A (BoNT-A) are performed in both therapeutics and aesthetics every year. However, there are 2 limitations with this very efficient treatment: its onset of action, it indeed takes a few days for the toxin to settle, and, most importantly, its duration, limited to 3 to 4 months. Patients need to come back regularly to get re-treated and, before the re-injection, the symptoms reappearance impacts their quality of life.
​
Fastox was created for accelerating the onset of botulinum toxin A (hence its name…) by combining it with a fast-acting mini-toxin from a marine shell. While testing this hypothesis, we serendipitously discovered that this mini-toxin could also significantly increase the duration of action of BoNT-A.
​
After screening approximately 200 molecules with similar activities, we selected our lead product FTP-501, the most potent BoNT-A duration enhancer with a very good safety profile.
FASTOX PRESENTATION VIDEO ON BFM TV
Fastox is a Remora venture
Remora Biotech SA is a venture portfolio Company based in Lausanne, Switzerland.
Founded by Jean-Marc Le Doussal and Partners in 2010,
Remora Biotech creates, finances and manages early-stage ventures developing innovative biologics in immunology and anti-aging.
Leadership team
Natalene HOEPFFNER
VP marketing & Business Development
Before joining Fastox, Natalene has been with Galderma... read more
Strategic Advisory Board
Giampietro Schiavo, PhD
Professor of Cellular Neuroscience
London, UK
Senior Group Leader at the Cancer Research UK London... read more
Technology
After screening approx. 200 molecules with similar activities, we selected our lead candidate FTP-501, the most potent BoNT-A enhancer with a very good safety profile.
​​
In-house laboratory
Fastox has a fully equipped 200m2 laboratory hosted at Remora Biotech facility in Nantes, France.
The laboratory has access to the Nantes University technical platforms.
Fastox a has dedicated technical team for animal experiments and can use Remora specialists in bioinformatics, animal models, biochemistry and cell biology.
Pipeline
FTP-501: Fastox lead candidate will be entering clinical stage in 2023.
​
The graph on the right represents a typical outcome of the DAS (digit abducting score) in rats showing an improvement of the FTP-501 combination with botulinum toxin A compared to the toxin alone. This improvement is consistent across all time points, from peak effect to return to baseline: we gain, on average, at each timepoint, one point on the DAS score (5-point scale).
These results are reproducible across experiments, labs and botulinum toxin doses and brands.
Fastox first patent “composition of matter” has been published in 2020: WO2020/254690
